Search | Clinical Trials Finder

Conditions: Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • Evanston, Illinois + 8 more

Conditions: Tricuspid Regurgitation
Interventions: Cardiac Magnetic Resonance; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Image Quality
Interventions: Suctioning orogastric tube which is attached to TEE probe cover; Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Transthyretin Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy
Interventions: 99mTc-pyrophosphate Single Photon Emission Computed Tomography; Diagnostic Test
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Healthy Participants
Interventions: Aficamten, Aficamten-matching Placebo, Moxifloxacin; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Embolic Stroke of Undetermined Source, Transient Ischemic Attack, Right-To-Left Atrial Shunt, Patent Foramen Ovale
Interventions: NeuralBot Investigational System, Transthoracic Echocardiography (TTE); Diagnostic Test
Lead sponsor: NeuraSignal Inc dba NovaSignal; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Phoenix, Arizona • Portland, Oregon • Chattanooga, Tennessee + 3 more

Conditions: Sleep Apnea Syndromes
Interventions: CPAP; Device
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions: Azacitidine, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab, Venetoclax; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 29
States / cities: Greenwich, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 23 more

Conditions: Breast Cancer Female, Adriamycin Toxicity
Interventions: 10,000 steps, Usual Care; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ventricular Dysfunction, Left, Ventricular Function, Left, Echocardiography, Ultrasonography, Point-of-Care Systems, Heart Function Tests, Stroke Volume, Federated Learning, Machine Learning, Artificial Intelligence (AI), Deep Learning, Neural Networks, Computer, Image Interpretation, Computer-Assisted, Diagnosis, Computer-Assisted, Sensitivity and Specificity, ROC Curve
Interventions: Focused Cardiac Point-of-Care Ultrasonography, FL-POCUS Federated Machine-Learning Analysis System; Diagnostic Test · Device
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: New York, New York

Conditions: Aortic Valve Stenosis
Interventions: Double Balloon Valvuloplasty in TAVR; Procedure
Lead sponsor: Community Memorial Health System; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Ventura, California

Conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, Brca2), Heart Diseases, Drug-Induced Cardiomyopathy
Interventions: echocardiography, Cardiopulmonary Exercise Testing, Blood Collection; Diagnostic Test · Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Critical Illness, Pediatrics
Interventions: Ultrasonic Cardiac Output Monitor (USCOM).; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Day to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Heart Failure
Interventions: Echocardiogram guided left ventricular lead placement; Procedure
Lead sponsor: Michigan Heart, PC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Ypsilanti, Michigan

Conditions: Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
Interventions: Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cardiopulmonary Disease
Interventions: Echocardiography, Pulmonary Gas Exchange; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Interferon Beta-1A, X-Ray Imaging, Echocardiography, Multigated Acquisition Scan, Computed Tomography, Positron Emission Tomography, Lumbar Puncture, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biopsy; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Mitral Valve Regurgitation, Congestive Heart Failure, Cardiomyopathy
Interventions: 3 dimensional echocardiography; Procedure
Lead sponsor: Juan Crestanello, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Left Ventricular Assist Device, Heart Failure, Intra-aortic Balloon Pump, LVAD Clot, LVAD-related GI Bleed
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cardiac Disease
Interventions: DEFINITY; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Tucson, Arizona • San Diego, California • Wilmington, Delaware + 6 more

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Fludarabine, Idarubicin, Multigated Acquisition Scan, Peripheral Blood Stem Cell, Questionnaire Administration, Recombinant Granulocyte Colony-Stimulating Factor, Total-Body Irradiation; Procedure · Drug · Biological + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cardiovascular Diseases, Arrhythmias, Cardiac, Atrial Fibrillation
Interventions: Intracardiac Echocardiography Catheter; Device
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Congenital Heart Disease
Interventions: Device-Aided performances, Device-Unaided performances; Device · Other
Lead sponsor: BrightHeart; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Pertuzumab, Radiologic Examination, Trastuzumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Staging Classification of Severe Tricuspid Regurgitation Using Novel Cardiac Imaging Techniques

TEE Image Quality Improvement With Our Devised Probe Cover

Bronx Transthyretin Amyloid Cardiomyopathy Database

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt

Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.

Federated Learning for Point-of-Care Cardiac Ultrasound

Transcatheter Aortic Valve Replacement (TAVR) Double Balloon Valvuloplasty

Genetics and Heart Health After Cancer Therapy

Comparing Cardiac Output Measurements in Critically Ill Children Using USCOM and Transthoracic ECHO

Localization of CRT According to Echocardiography: LOCATE-Pilot Study

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Unmasking Right Ventricular and Pulmonary Derangements With Exercise and Oxygen in Early Stage Cardiopulmonary Diseases

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy

Pulse Wave Analysis in Advanced Heart Failure

DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Intracardiac Echocardiography Catheter Supply-Chain Reliability and Clinical Access Study

Fetal Heart Ultrasound Suspicious Radiographic Finding Identification - Reader Study

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)